NCT06579196View on ClinicalTrials.gov

Trabedersen (OT-101) With Pembrolizumab for Newly Diagnosed Advanced NSCLC and Positive PD-L1

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

May 12, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

February 28, 2029

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Trabedersen

Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).

DRUG

Pembrolizumab

Pembrolizumab is a humanized anti-programmed death (PD-1) monoclonal antibody.

Trial Locations (1)

68198

RECRUITING

University of Nebraska Medical Center, Omaha

All Listed Sponsors
lead

University of Nebraska

OTHER